These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11324112)

  • 21. HIV-1 therapeutic vaccines.
    Kinloch-de Loes S; Autran B
    J Infect; 2002 Apr; 44(3):152-9. PubMed ID: 12099741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trends in pregnancy rates among women with human immunodeficiency virus.
    Blair JM; Hanson DL; Jones JL; Dworkin MS
    Obstet Gynecol; 2004 Apr; 103(4):663-8. PubMed ID: 15051556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
    Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [CD4+ guided interruption HAART in HIV patients].
    Antolini D; Lanzafame M; Lattuada E; Vento S; Concia E
    Recenti Prog Med; 2007 Oct; 98(10):501-5. PubMed ID: 17970175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The relationship of pregnancy to the use of highly active antiretroviral therapy.
    Minkoff H; Ahdieh L; Watts H; Greenblatt RM; Schmidt J; Schneider M; Stek A
    Am J Obstet Gynecol; 2001 May; 184(6):1221-7. PubMed ID: 11349192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
    Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K
    Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Summaries from the Eleventh Annual Houston Conference on AIDS in America.
    Res Initiat Treat Action; 1999 Jul; 5(3):13-25. PubMed ID: 11366719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bridging the gap?
    del Rio C; Soto-Ramirez LE
    AIDS Clin Care; 1998 Sep; 10(9):65-7, 69, 72. PubMed ID: 11365808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004.
    Nesheim SR; Kapogiannis BG; Soe MM; Sullivan KM; Abrams E; Farley J; Palumbo P; Koenig LJ; Bulterys M
    Pediatrics; 2007 Jul; 120(1):100-9. PubMed ID: 17606567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005.
    Buchacz K; Baker RK; Moorman AC; Richardson JT; Wood KC; Holmberg SD; Brooks JT;
    AIDS; 2008 Jul; 22(11):1345-54. PubMed ID: 18580614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.
    Adjé-Touré CA; Cheingsong R; Garcìa-Lerma JG; Eholié S; Borget MY; Bouchez JM; Otten RA; Maurice C; Sassan-Morokro M; Ekpini RE; Nolan M; Chorba T; Heneine W; Nkengasong JN
    AIDS; 2003 Jul; 17 Suppl 3():S49-54. PubMed ID: 14565609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
    Tai JH; Udoji MA; Barkanic G; Byrne DW; Rebeiro PF; Byram BR; Kheshti A; Carter JD; Graves CR; Raffanti SP; Sterling TR
    J Infect Dis; 2007 Oct; 196(7):1044-52. PubMed ID: 17763327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.
    Gandhi T; Wei W; Amin K; Kazanjian P
    Clin Infect Dis; 2006 Mar; 42(6):878-84. PubMed ID: 16477568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug resistance among HIV-infected pregnant women receiving antiretrovirals for prophylaxis.
    Duran AS; Losso MH; Salomón H; Harris DR; Pampuro S; Soto-Ramirez LE; Duarte G; de Souza RS; Read JS;
    AIDS; 2007 Jan; 21(2):199-205. PubMed ID: 17197811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [HIV infection: future perspective for a so-called fatal disease?].
    von Overbeck J; Iten A
    Schweiz Med Wochenschr; 1997 Mar; 127(13):521-7. PubMed ID: 9190663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.
    Golub ET; Benning L; Sharma A; Gandhi M; Cohen MH; Young M; Gange SJ
    Clin Infect Dis; 2008 Jan; 46(2):305-12. PubMed ID: 18171267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
    Fagard C; Oxenius A; Günthard H; Garcia F; Le Braz M; Mestre G; Battegay M; Furrer H; Vernazza P; Bernasconi E; Telenti A; Weber R; Leduc D; Yerly S; Price D; Dawson SJ; Klimkait T; Perneger TV; McLean A; Clotet B; Gatell JM; Perrin L; Plana M; Phillips R; Hirschel B;
    Arch Intern Med; 2003 May; 163(10):1220-6. PubMed ID: 12767960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Viral pathogenesis and opportunistic infections.
    Gupta G
    J Calif Dent Assoc; 1993 Sep; 21(9):29-36. PubMed ID: 7508496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment for human immunodeficiency virus (HIV) infection.
    Eberle S
    West J Med; 1997 Sep; 167(3):175-6. PubMed ID: 9308411
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.